Alendronate induced subacute cutaneous lupus erythematosus successfully treated with intravenous immunoglobulin
Yazar
Sar, Mehmet
Bayazit, Samet
Askin, Ozge
Engin, Burhan
Ugurlu, Serdal
Serdaroglu, Server
Uzuncakmak, Tugba Kevser
Üst veri
Tüm öğe kaydını gösterÖzet
The subacute cutaneous lupus erythematosus (SCLE) is a distinct subtype of lupus erythematosus (LE) representing specific clinical and serological features. Almost 20%-30% of the cases with SCLE are predicted to associated with medications. Thiazide diuretics, terbinafine, antiepileptic, and proton pump inhibitors are the best-known drugs to induce drug-related SCLE. Herein we want to present a 65-year-old female with alendronate induced SCLE, resistant to classical therapies, and respond well to intravenous immunoglobulin (IVIG), suggesting that IVIG could be an alternative treatment in patients resistant to classical treatment protocols.
Koleksiyonlar
- Makale [92796]